

Chairman's Message



We will strengthen governance to evolve into a truly global company.

Over the past year, we have undertaken many very important projects, such as the new medium-term plan MTP2025 announced in May 2021. CEO Shigeo Taniuchi and the rest of the Board of Directors have engaged in rigorous, free and open discussions involving productive opinion exchange and were able to make quick and appropriate decisions. As Chairman of the Board of Directors, in fiscal 2021, I will continue to strengthen the effectiveness of the Board with the goal of further enhancing the transparency and objectivity of management.

Fiscal 2021 is also the first year of MTP2025. We will take on new challenges while maximizing the value of our core business of prescription ophthalmic pharmaceuticals. Management supervision using enhanced monitoring mechanisms will be more important than ever, particularly in discussing R&D and investments in new fields. Whilst other companies may have larger boards, members of Santen's Board of Directors reflect a wide range of backgrounds, from the life science business to global management, ESG and social contribution. We will proactively remain engaged in strategic discussions whilst gathering the relevant information from our executives.

Santen wants to evolve into a truly global ophthalmology company. Ensuring transparency, objectivity and appropriateness of management to improve corporate value and shareholder value is the core tenet of Santen's governance, in which constant evolution remains important to allow us to address changes in the business environment. We will contribute to a further evolution in our governance by listening sincerely to the opinions we obtain throughout our dialogues with investors and other stakeholders.

A handwritten signature in black ink that reads "A. Kurokawa".

Akira Kurokawa

Representative Director
Chairman